INBX Phase 2 readout: a negative outcome, -5.6%

On September 8, 2026, Inhibrx Biosciences, Inc. reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.6% in the window around the event. It had already run +36.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.